Analysis of genomic alterations and treatment landscape in patients with advanced tumors using real-world data for precision oncology.
Karagoz K, Ayers K, Patel B, Wells J, Newman S, Oh W, Zhou X, Chen R, Guin S. Analysis of genomic alterations and treatment landscape in patients with advanced tumors using real-world data for precision oncology. Journal Of Clinical Oncology 2022, 40: 6584-6584. DOI: 10.1200/jco.2022.40.16_suppl.6584.Peer-Reviewed Original ResearchTumor mutational burdenOverall survivalCancer typesTargetable mutationsPatient outcomesNext-generation sequencingNGS resultsSingle large healthcare systemElectronic medical record dataPositive NGS resultsTMB-low patientsOutcomes of patientsStage 4 patientsMultiple myeloma patientsLung cancer patientsSignificant survival differenceGenomic alterationsStage 3Medical record dataLarge healthcare systemMicrosatellite instability statusRelevant clinical questionsNCCN guidelinesClinical responseTreatment landscapeLandscape of tumor genetic testing and targeted therapies over an eight-year span in a rural population.
Williams C, Guin S, Elsey R, Meißner T, Xu B, Sun Y, Amallraja A, Jun T, Schadt E, Chen R, Zhou X, Higashi M, Lee J, Oh W. Landscape of tumor genetic testing and targeted therapies over an eight-year span in a rural population. Journal Of Clinical Oncology 2022, 40: e15036-e15036. DOI: 10.1200/jco.2022.40.16_suppl.e15036.Peer-Reviewed Original ResearchAdvanced breast cancer patientsBreast cancer patientsTargeted therapyTargetable mutationsCancer patientsElectronic medical recordsNCCN guidelinesLabel useBRCA1/2 mutationsStage IIITumor typesNon-small cell lung cancerAdvanced prostate cancer patientsKRAS/NRAS mutationsReal-world patient populationPositive NGS resultsAdvanced breast cancerNGS resultsAdvanced-stage patientsCell lung cancerBRAF V600 mutationTumor molecular profilingProstate cancer patientsTumor genetic testingMolecular tumor board
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply